Skip to main content

Advertisement

SpringerLink
Log in

Re-Appraisal of Estrogen Receptor Negative/Progesterone Receptor Positive (ER−/PR+) Breast Cancer Phenotype: True Subtype or Technical Artefact?

  • Original Article
  • Published:
Pathology & Oncology Research

Abstract

Expression of the ER and PR receptors is routinely quantified in breast cancer as a predictive marker of response to hormonal therapy. Accurate determination of ER and PR status is critical to the optimal selection of patients for targeted therapy. The existence of an ER−/PR+ subtype is controversial, with debate centred on whether this represents a true phenotype or a technical artefact on immunohistochemistry (IHC). The aim of this study was to investigate the true incidence and clinico-pathological features of ER−/PR+ breast cancers in a tertiary referral symptomatic breast unit. Clinico-pathological data were collected on invasive breast cancers diagnosed between 1995 and 2005. IHC for ER and PR receptors was repeated on all cases which were ER−/PR+, with the same paraffin block used for the initial diagnostic testing. Concordance between the diagnostic and repeat IHC was determined using validated testing. Complete data, including ER and PR status were available for 697 patients diagnosed during the study period. On diagnostic IHC, the immunophenotype of the breast tumours was: ER+/PR+ in 396 (57%), ER−/PR- in 157 (23%), ER+/PR- in 88 (12%) and ER−/PR+ in 56 (8.6%) patients. On repeat IHC of 48/56 ER−/PR+ tumours 45.8% were ER+/PR+, 6% were ER+/PR- and 43.7% were ER−/PR- None of the cases were confirmed to be ER−/PR+. The ER−/PR+ phenotypic breast cancer is likely to be the result of technical artefact. Prompt reassessment of patients originally assigned to this subtype who re-present with symptoms should be considered to ensure appropriate clinical management.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Anderson WF, Chatterjee N, Ershler WB et al (2002) Estrogen receptor breast cancer phenotypes in the surveillance, epidemiology, and end results database. Breast Cancer Res Treat 76:27–36

    Article  PubMed  CAS  Google Scholar 

  2. Nadji M, Gomez-Fernandez C, Ganjei-Azar P et al (2005) Immunohistochemistry of estrogen and progesterone receptors reconsidered: experience with 5,993 breast cancers. Am J Clin Pathol 123:21–27

    Article  PubMed  Google Scholar 

  3. Early Breast Cancer Trialists’ Collaborative Group (2011) Relevance of breast cancer hormone receptors and other factors to the efficacy of adjuvant tamoxifen: patient-level meta-analysis of randomised trials. Lancet 378(9793):771–784

    Article  CAS  Google Scholar 

  4. Ng CH, Pathy NB, Taib NA, Mun KS, Rhodes A, Yip CH (2012) The estrogen receptor negative-progesterone receptor positive breast carcinoma is a biological entity and not a technical artifact. Asian Pac J Cancer Prev 13(4):1111–1113

    Article  PubMed  Google Scholar 

  5. Maleki Z, Shariat S, Mokri M, Atri M (2012) ER-negative /PR-positive breast carcinomas or technical artifacts in immunohistochemistry? Arch Iran Med 15(6):366–369

    PubMed  Google Scholar 

  6. Hammond ME, Hayes DF, Dowsett M, Allred DC, Hagerty KL et al (2010) American Society of Clinical Oncology/College of American Pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer. J Clin Oncol 28(16):2784–2795

    Article  PubMed  PubMed Central  Google Scholar 

  7. Rakha EA, El-Sayed ME, Green AR, Paish EC, Powe DG, Gee J et al (2007) Biologic and clinical characteristics of breast cancer with single hormone receptor positive phenotype. J Clin Oncol 25(30):4772–4778

    Article  PubMed  Google Scholar 

  8. De Maeyer L, Van Limbergen E, De Nys K, Moerman P, Pochet N, Hendrickx W et al (2008) Does Estrogen receptor-negative/progesterone receptor-positive breast carcinoma exist? J Clin Oncol 26(2):335–336

    Article  PubMed  Google Scholar 

  9. Colditz GA, Rosner BA, Chen WY, Holmes MD, Hankinson SE (2004) Risk factors for breast cancer according to estrogen and progesterone receptor status. JNCI J Natl Cancer Inst 96(3):218–228

    Article  PubMed  CAS  Google Scholar 

  10. Yu KD, Di GH, Wu J, Lu JS, Shen KW, Lu GY et al (2008) Breast cancer patients with estrogen receptor-negative/progesterone receptor-positive tumors: being younger and getting less benefit from adjuvant tamoxifen treatment. J Cancer Res Clin Oncol 134(12):1347–1354

    Article  PubMed  CAS  Google Scholar 

  11. Kiani J, Khan A, Khawar H, Shuaib F, Pervez S (2006) ER-alpha negative and PR-positive breast cancer: lab error or clinical entity? Pathol Oncol Res 12(4):223–227

    Article  PubMed  Google Scholar 

  12. Shen T, Brandwein Gensler M, Hameed O, Siegal GP, Wei S (2015) Characterization of estrogen receptor–negative/progesterone receptor–positive breast cancer. Hum Pathol 46(11):1776–1784

    Article  PubMed  CAS  Google Scholar 

  13. Dunwald LK, Rossing MA, Li CI (2007) Hormone receptor status, tumor characteristics, and prognosis: a prospective cohort of breast cancer patients. Breast Cancer Res 9(1):R6

    Article  CAS  Google Scholar 

  14. Rhodes A, Jasani B, Balaton AJ, Barnes DM, Miller KD (2000) Frequency of oestrogen and progesterone receptor positivity by immunohistochemical analysis in 7016 breast carcinomas: correlation with patient age, assay sensitivity, threshold value, and mammographic screening. J Clin Pathol 53:688–696

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  15. Gown AM (2008) Current issues in ER and HER2 testing by IHC in breast cancer. Mod Pathol 21(Suppl 2):S8–15

    Article  PubMed  CAS  Google Scholar 

  16. Schnitt SJ (2006) Estrogen receptor testing of breast cancer in current clinical practice: What’s the question? J Clin Oncol 24(12):1797–1799

    Article  PubMed  Google Scholar 

  17. Goldstein NS, Ferkowicz M, Odish E et al (2003) Minimum formalin fixation time for consistent estrogen receptor immunohistochemical staining of invasive breast carcinoma. Am J Clin Pathol 120:86–92

    Article  PubMed  Google Scholar 

  18. Williams JH, Mepham BL, Wright DH (1997) Tissue preparation for immunocytochemistry. J Clin Pathol 50:422–428

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  19. van Diest PJ, van Dam P, Henzen-Longmans SC et al (1997) A scoring system for immunohistochemical staining: consensus report of the task force for basic research EORTC-GCCG. J Clin Pathol 50:801–804

    Article  PubMed  PubMed Central  Google Scholar 

  20. Larsson LI (1993) Tissue preparation methods for light microscopic immunohistochemistry. Appl Immunohistochem 1:2–16

    Google Scholar 

  21. Rhodes A, Jasani B, Balaton AJ, Barnes DM, Anderson E, Bobrow LG et al (2001) Study of interlaboratory reliability and reproducibility of estrogen andprogesterone receptor assays in Europe. Documentation of poor reliability and identification of insufficient microwave antigen retrieval time as a major contributory element of unreliable assays. Am J Clin Pathol 115(1):44–58

    Article  PubMed  CAS  Google Scholar 

  22. Harvey JM, Clark GM, Osborne CK, Allred DC (1999) Estrogen Receptor Status by Immunohistochemistry Is Superior to the Ligand-Binding Assay for Predicting Response to Adjuvant Endocrine Therapy in Breast Cancer. J Clin Oncol 17(5):1474–1481

    Article  PubMed  CAS  Google Scholar 

  23. Chan M, Chang MC, Gonzalez R, Lategan B, del Barco E, Vera-Badillo F et al (2015) Outcomes of estrogen receptor negative and progesterone receptor positive breast cancer. PLoS One 10(7):e0132449

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  24. Hefti MM, Hu R, Knoblauch NW, Collins LC, Haibe-Kains B, Tamimi RM, Beck AH (2013) Estrogen receptor negative/progesterone receptor positive breast cancer is not a reproducible subtype. Breast Cancer Res 15(4):R68

    Article  PubMed  PubMed Central  CAS  Google Scholar 

Download references

Author information

Author notes

  1. Authorship

    Each author contributed equally to this work. All authors were involved in manuscript preparation and editing of the final draft.

    Key Messages

    ER−/PR+ breast cancer is a disputed entity in the published literature.

    We could not confirm the distinct presence of ER−/PR+ breast cancer on retesting.

    Repeat testing is recommended, to rule out a false negative ER result.

Authors and Affiliations

  1. Department of Surgery, University College Hospital Galway, Galway, Ireland

    Niamh M. Foley, J. M. Coll, A. J. Lowery, S. O. Hynes, M. J. Kerin, M. Sheehan, C. Brodie & K. J. Sweeney

Authors
  1. Niamh M. Foley
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. J. M. Coll
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. A. J. Lowery
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. S. O. Hynes
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. M. J. Kerin
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. M. Sheehan
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. C. Brodie
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. K. J. Sweeney
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Niamh M. Foley.

Ethics declarations

Conflict of Interest

The authors have no conflicts of interest to declare.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Foley, N.M., Coll, J.M., Lowery, A.J. et al. Re-Appraisal of Estrogen Receptor Negative/Progesterone Receptor Positive (ER−/PR+) Breast Cancer Phenotype: True Subtype or Technical Artefact?. Pathol. Oncol. Res. 24, 881–884 (2018). https://doi.org/10.1007/s12253-017-0304-5

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s12253-017-0304-5

Keywords

Search

Navigation